Sanofi's type 2 diabetes product Adlyxin (lixisenatide) has scooped up FDA approval with labeling that appears markedly similar to existing therapies for the disease.
The sixth GLP-1 product to enter the U.S. market, Adlyxin was approved as a treatment for adults to improve glycemic...





